In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (QURE), with a price target of $100. The company’s shares closed yesterday at $57.28.
Amusa said:
“We expect 1-year follow-up data at ASH 2019. Reiteration: The updated phase IIb data (2 of 3 patients now have FIX activity in the normal range), continue to support a blockbuster opportunity for AMT-061 to make hemophilia B patients phenotypically normal. As might be expected to be associated with 47% mean FIX activity for AMT-061, uniQure reported treated patients “show no loss of FIX activity, no bleeding events and no need for infusions of FIX replacement therapy.” By contrast, patients had 3, 1, and 5 spontaneous bleeds preceding treatment with AMT-061.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.0% and a 50.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Iovance Biotherapeutics Inc, and Logicbio Therapeutics Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $78.67, representing a 37.3% upside. In a report issued on April 30, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.
See today’s analyst top recommended stocks >>
Based on uniQure NV’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.77 million. In comparison, last year the company had a GAAP net loss of $18.79 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
